| Indication | – Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. – Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. – Adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. |
| Status | FDA NDA final approval |
| Product Advantages | – Phyrago® (Dasatinib) is an oral kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It can be used concomitantly with certain acid-reducing agents, such as proton pump inhibitors (PPIs) and H2 blockers. – Exclusivity: 3 years |
| Market Size | According to research institution estimates, the U.S. market sales of the original drug in 2025 were approximately US$900 million, with several generic drug manufacturers competing alongside the original manufacturer. |
?
R&D
